Ke Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ke Yang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Attaya Suvannasankha
Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA
20 shared publications - Brent Smith
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana
20 shared publications - Brian A. Walker
Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States
20 shared publications - Enze Liu
Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States
20 shared publications - Faiza Zafar
Genentech Inc., South San Francisco, California
20 shared publications - Gareth John Morgan
Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
20 shared publications
Latest Publications
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Identification of the Distinct Immune Microenvironment Features Associated with Progression Following High-Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma
Supplementary Table S3. Major cell population proportions in pre-and post-ASCT samples
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Identification of the Distinct Immune Microenvironment Features Associated with Progression Following High-Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma
Supplementary Table S3. Major cell population proportions in pre-and post-ASCT samples
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Identification of the Distinct Immune Microenvironment Features Associated with Progression Following High-Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma
NK cell CD56bright/CD56dim ratio is associated with progression. A, UMAP of NK cells identifying three populations. B, NK cell populations are defined by the expression of CD56 (NCAM1) and NKG7. C, Expression of CD56 (NCAM1) in CD56bright and CD56dim cells. D, NK cell populations do not differ between progression states except for CD56dim NK cells after ASCT. E, The ratio of CD56bright to CD56dim cells is significantly different after ASCT. NP, nonprogressors; P, progressors.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Identification of the Distinct Immune Microenvironment Features Associated with Progression Following High-Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma
NK cell CD56bright/CD56dim ratio is associated with progression. A, UMAP of NK cells identifying three populations. B, NK cell populations are defined by the expression of CD56 (NCAM1) and NKG7. C, Expression of CD56 (NCAM1) in CD56bright and CD56dim cells. D, NK cell populations do not differ between progression states except for CD56dim NK cells after ASCT. E, The ratio of CD56bright to CD56dim cells is significantly different after ASCT. NP, nonprogressors; P, progressors.